Able 0 4 0 4 O
to 5 7 5 7 O
be 8 10 8 10 O
off 11 14 11 14 O
corticosteroids 15 30 15 30 B-treatment
and 31 34 31 34 O
any 35 38 35 38 O
other 39 44 39 44 O
immune 45 51 45 51 B-treatment
suppressive 52 63 52 63 I-treatment
medications 64 75 64 75 I-treatment
beginning 76 85 76 85 O
on 86 88 86 88 O
Day 89 92 89 92 O
-3 93 95 93 95 O
and 96 99 96 99 O
continuing 100 110 100 110 O
until 111 116 111 116 O
30 117 119 117 119 B-upper_bound
days 120 124 120 124 I-upper_bound
after 125 130 125 130 I-upper_bound
the 131 134 131 134 O
infusion 135 143 135 143 O
of 144 146 144 146 O
the 147 150 147 150 O
CIML 151 155 151 155 B-treatment
NK 156 158 156 158 I-treatment
cells 159 164 159 164 I-treatment

Age 0 3 165 168 B-age
requirement 4 15 169 180 O
for 16 19 181 184 O
pediatric 20 29 185 194 B-clinical_variable
cohort 30 36 195 201 I-clinical_variable
: 36 37 201 202 O
2 38 39 203 204 B-lower_bound
- 39 40 204 205 O
17 40 42 205 207 B-upper_bound
years 43 48 208 213 I-upper_bound
of 49 51 214 216 O
age 52 55 217 220 B-age

Age 0 3 221 224 B-age
requirement 4 15 225 236 O
for 16 19 237 240 O
phase 20 25 241 246 O
I 26 27 247 248 O
and 28 31 249 252 O
phase 32 37 253 258 O
II 38 40 259 261 O
patients 41 49 262 270 O
: 49 50 270 271 O
At 51 53 272 274 O
least 54 59 275 280 O
18 60 62 281 283 B-lower_bound
years 63 68 284 289 I-lower_bound
of 69 71 290 292 O
age 72 75 293 296 B-age

At 0 2 297 299 O
least 3 8 300 305 O
18 9 11 306 308 B-lower_bound
years 12 17 309 314 I-lower_bound
of 18 20 315 317 O
age 21 24 318 321 B-age

Available 0 9 322 331 O
HLA 10 13 332 335 B-clinical_variable
- 13 14 335 336 I-clinical_variable
haploidentical 14 28 336 350 I-clinical_variable
donor 29 34 351 356 O

CNS 0 3 357 360 B-treatment
therapy 4 11 361 368 I-treatment
( 12 13 369 370 O
chemotherapy 13 25 370 382 B-treatment
or 26 28 383 385 O
radiation 29 38 386 395 B-treatment
) 38 39 395 396 O
should 40 46 397 403 O
continue 47 55 404 412 O
as 56 58 413 415 O
medically 59 68 416 425 O
indicated 69 78 426 435 O
during 79 85 436 442 O
the 86 89 443 446 O
study 90 95 447 452 O
treatment 96 105 453 462 B-treatment

Circulating 0 11 463 474 O
blast 12 17 475 480 B-clinical_variable
count 18 23 481 486 I-clinical_variable
≥30,000/µL 24 34 487 497 O
by 35 37 498 500 O
morphology 38 48 501 511 O
or 49 51 512 514 O
flow 52 56 515 519 O
cytometry 57 66 520 529 O

Favorable 0 9 530 539 O
- 9 10 539 540 O
risk 10 14 540 544 O
core 15 19 545 549 B-cancer
binding 20 27 550 557 I-cancer
factor 28 34 558 564 I-cancer
( 35 36 565 566 I-cancer
CBF 36 39 566 569 I-cancer
) 39 40 569 570 I-cancer
mutated 41 48 571 578 O
AML 49 52 579 582 B-cancer
and 53 56 583 586 I-cancer
acute 57 62 587 592 I-cancer
promyelocytic 63 76 593 606 I-cancer
leukemia 77 85 607 615 I-cancer
( 86 87 616 617 I-cancer
APL 87 90 617 620 I-cancer
) 90 91 620 621 I-cancer

Female 0 6 622 628 B-gender
and 7 10 629 632 I-gender
male 11 15 633 637 I-gender
patients 16 24 638 646 I-gender
( 25 26 647 648 O
along 26 31 648 653 O
with 32 36 654 658 O
their 37 42 659 664 O
female 43 49 665 671 B-gender
partners 50 58 672 680 I-gender
) 58 59 680 681 O
must 60 64 682 686 O
agree 65 70 687 692 B-contraception_consent
to 71 73 693 695 I-contraception_consent
use 74 77 696 699 I-contraception_consent
two 78 81 700 703 I-contraception_consent
forms 82 87 704 709 I-contraception_consent
of 88 90 710 712 I-contraception_consent
acceptable 91 101 713 723 I-contraception_consent
contraception 102 115 724 737 I-contraception_consent
, 115 116 737 738 I-contraception_consent
including 117 126 739 748 I-contraception_consent
one 127 130 749 752 I-contraception_consent
barrier 131 138 753 760 I-contraception_consent
method 139 145 761 767 I-contraception_consent
, 145 146 767 768 O
during 147 153 769 775 O
participation 154 167 776 789 O
in 168 170 790 792 O
the 171 174 793 796 O
study 175 180 797 802 O
and 181 184 803 806 O
throughout 185 195 807 817 O
the 196 199 818 821 O
DLT 200 203 822 825 O
evaluation 204 214 826 836 O
period 215 221 837 843 O

However 0 7 844 851 O
, 7 8 851 852 O
use 9 12 853 856 O
of 13 15 857 859 O
low 16 19 860 863 O
- 19 20 863 864 O
level 20 25 864 869 O
corticosteroids 26 41 870 885 B-treatment
is 42 44 886 888 O
permitted 45 54 889 898 O
if 55 57 899 901 O
deemed 58 64 902 908 O
medically 65 74 909 918 O
necessary 75 84 919 928 O
. 84 85 928 929 O
Low 86 89 930 933 O
- 89 90 933 934 O
level 90 95 934 939 O
corticosteroid 96 110 940 954 O
use 111 114 955 958 O
is 115 117 959 961 O
defined 118 125 962 969 O
as 126 128 970 972 O
10 129 131 973 975 B-upper_bound
mg 131 133 975 977 I-upper_bound
or 134 136 978 980 O
less 137 141 981 985 O
of 142 144 986 988 O
prednisone 145 155 989 999 B-treatment
( 156 157 1000 1001 O
or 157 159 1001 1003 O
equivalent 160 170 1004 1014 O
for 171 174 1015 1018 O
other 175 180 1019 1024 O
steroids 181 189 1025 1033 O
) 189 190 1033 1034 O
per 191 194 1035 1038 O
day 195 198 1039 1042 O

In 0 2 1043 1045 O
general 3 10 1046 1053 O
good 11 15 1054 1058 O
health 16 22 1059 1065 O
, 22 23 1065 1066 O
and 24 27 1067 1070 O
medically 28 37 1071 1080 O
able 38 42 1081 1085 O
to 43 45 1086 1088 O
tolerate 46 54 1089 1097 O
leukapheresis 55 68 1098 1111 B-treatment
required 69 77 1112 1120 O
for 78 81 1121 1124 O
harvesting 82 92 1125 1135 O
the 93 96 1136 1139 O
NK 97 99 1140 1142 O
cells 100 105 1143 1148 O
for 106 109 1149 1152 O
this 110 114 1153 1157 O
study 115 120 1158 1163 O

Infiltrates 0 11 1164 1175 O
attributed 12 22 1176 1186 O
to 23 25 1187 1189 O
infection 26 35 1190 1199 B-chronic_disease
must 36 40 1200 1204 O
be 41 43 1205 1207 O
stable/ 44 51 1208 1215 O
improving 52 61 1216 1225 O
after 62 67 1226 1231 B-upper_bound
1 68 69 1232 1233 I-upper_bound
week 70 74 1234 1238 I-upper_bound
of 75 77 1239 1241 O
appropriate 78 89 1242 1253 O
therapy 90 97 1254 1261 B-treatment
( 98 99 1262 1263 O
4 99 100 1263 1264 O
weeks 101 106 1265 1270 O
for 107 110 1271 1274 O
presumed 111 119 1275 1283 O
or 120 122 1284 1286 O
proven 123 129 1287 1293 O
fungal 130 136 1294 1300 B-chronic_disease
infections 137 147 1301 1311 I-chronic_disease
) 147 148 1311 1312 O

Isolated 0 8 1313 1321 B-cancer
extramedullary 9 23 1322 1336 I-cancer
relapse 24 31 1337 1344 I-cancer
( 32 33 1345 1346 O
phase 33 38 1346 1351 O
II 39 41 1352 1354 O
only 42 46 1355 1359 O
) 46 47 1359 1360 O

Karnofsky 0 9 1361 1370 B-clinical_variable
/ 9 10 1370 1371 O
Lansky 10 16 1371 1377 B-clinical_variable
performance 17 28 1378 1389 I-clinical_variable
status 29 35 1390 1396 I-clinical_variable
≥ 36 37 1397 1398 O
50 38 40 1399 1401 B-lower_bound
% 41 42 1402 1403 I-lower_bound

Known 0 5 1404 1409 O
hypersensitivity 6 22 1410 1426 O
to 23 25 1427 1429 O
one 26 29 1430 1433 O
or 30 32 1434 1436 O
more 33 37 1437 1441 O
of 38 40 1442 1444 O
the 41 44 1445 1448 O
study 45 50 1449 1454 B-allergy_name
agents 51 57 1455 1461 I-allergy_name

More 0 4 1462 1466 O
than 5 9 1467 1471 O
one 10 13 1472 1475 B-lower_bound
course 14 20 1476 1482 O
of 21 23 1483 1485 O
salvage 24 31 1486 1493 B-treatment
chemotherapy 32 44 1494 1506 I-treatment
for 45 48 1507 1510 O
primary 49 56 1511 1518 O
induction 57 66 1519 1528 O
failure 67 74 1529 1536 O
or 75 77 1537 1539 O
AML 78 81 1540 1543 B-cancer
relapsing 82 91 1544 1553 O
after 92 97 1554 1559 O
CR1 98 101 1560 1563 B-cancer
( 102 103 1564 1565 O
phase 103 108 1565 1570 O
II 109 111 1571 1573 O
only 112 116 1574 1578 O
) 116 117 1578 1579 O

Negative 0 8 1580 1588 O
for 9 12 1589 1592 O
hepatitis 13 22 1593 1602 B-chronic_disease
, 22 23 1602 1603 O
HTLV 24 28 1604 1608 B-cancer
, 28 29 1608 1609 O
and 30 33 1610 1613 O
HIV 34 37 1614 1617 B-chronic_disease
on 38 40 1618 1620 O
donor 41 46 1621 1626 O
viral 47 52 1627 1632 O
screen 53 59 1633 1639 O

New 0 3 1640 1643 O
progressive 4 15 1644 1655 O
pulmonary 16 25 1656 1665 O
infiltrates 26 37 1666 1677 O
on 38 40 1678 1680 O
screening 41 50 1681 1690 O
chest 51 56 1691 1696 B-treatment
x 57 58 1697 1698 I-treatment
- 58 59 1698 1699 I-treatment
ray 59 62 1699 1702 I-treatment
or 63 65 1703 1705 O
chest 66 71 1706 1711 B-treatment
CT 72 74 1712 1714 I-treatment
scan 75 79 1715 1719 I-treatment
that 80 84 1720 1724 O
have 85 89 1725 1729 O
not 90 93 1730 1733 O
been 94 98 1734 1738 O
evaluated 99 108 1739 1748 O
with 109 113 1749 1753 O
bronchoscopy 114 126 1754 1766 B-treatment

Not 0 3 1767 1770 B-pregnancy
pregnant 4 12 1771 1779 I-pregnancy

OR 0 2 1780 1782 O
High 3 7 1783 1787 O
- 7 8 1787 1788 O
risk 8 12 1788 1792 O
AML 13 16 1793 1796 O
( 17 18 1797 1798 O
by 18 20 1798 1800 O
ELN 21 24 1801 1804 O
criteria 25 33 1805 1813 O
; 33 34 1813 1814 O
See 35 38 1815 1818 O
Appendix 39 47 1819 1827 O
C 48 49 1828 1829 O
) 49 50 1829 1830 O
in 51 53 1831 1833 O
complete 54 62 1834 1842 O
remission 63 72 1843 1852 O
( 73 74 1853 1854 O
CR 74 76 1854 1856 O
) 76 77 1856 1857 O
and 78 81 1858 1861 O
has 82 85 1862 1865 O
either 86 92 1866 1872 O
refused 93 100 1873 1880 O
hematopoietic 101 114 1881 1894 B-treatment
stem 115 119 1895 1899 I-treatment
cell 120 124 1900 1904 I-treatment
transplantation 125 140 1905 1920 I-treatment
OR 141 143 1921 1923 O
is 144 146 1924 1926 O
currently 147 156 1927 1936 O
not 157 160 1937 1940 O
eligible 161 169 1941 1949 O
for 170 173 1950 1953 O
hematopoietic 174 187 1954 1967 O
stem 188 192 1968 1972 O
cell 193 197 1973 1977 O
transplantation 198 213 1978 1993 O
OR 214 216 1994 1996 O
for 217 220 1997 2000 O
whom 221 225 2001 2005 O
hematopoietic 226 239 2006 2019 O
stem 240 244 2020 2024 O
cell 245 249 2025 2029 O
transplantation 250 265 2030 2045 O
is 266 268 2046 2048 O
being 269 274 2049 2054 O
reserved 275 283 2055 2063 O
for 284 287 2064 2067 O
later 288 293 2068 2073 O
relapse 294 301 2074 2081 O
. 301 302 2081 2082 O
This 303 307 2083 2087 O
is 308 310 2088 2090 O
inclusive 311 320 2091 2100 O
of 321 323 2101 2103 O
patients 324 332 2104 2112 O
with 333 337 2113 2117 O
minimal 338 345 2118 2125 B-cancer
residual 346 354 2126 2134 I-cancer
disease 355 362 2135 2142 I-cancer
evidenced 363 372 2143 2152 O
by 373 375 2153 2155 O
cytogenetics 376 388 2156 2168 B-treatment
, 388 389 2168 2169 O
molecular 390 399 2170 2179 B-treatment
testing 400 407 2180 2187 I-treatment
, 407 408 2187 2188 O
and/or 409 415 2189 2195 O
flow 416 420 2196 2200 B-treatment
cytometry 421 430 2201 2210 I-treatment

OR 0 2 2211 2213 O
Myelodysplastic 3 18 2214 2229 B-cancer
syndrome 19 27 2230 2238 I-cancer
( 28 29 2239 2240 I-cancer
MDS 29 32 2240 2243 I-cancer
) 32 33 2243 2244 I-cancer
with 34 38 2245 2249 O
excess 39 45 2250 2256 B-clinical_variable
blasts 46 52 2257 2263 I-clinical_variable
( 53 54 2264 2265 O
> 54 55 2265 2266 O
5 55 56 2266 2267 B-lower_bound
% 56 57 2267 2268 I-lower_bound
) 57 58 2268 2269 O
and 59 62 2270 2273 O
progressive 63 74 2274 2285 B-chronic_disease
disease 75 82 2286 2293 I-chronic_disease
at 83 85 2294 2296 O
any 86 89 2297 2300 O
time 90 94 2301 2305 O
after 95 100 2306 2311 O
initiation 101 111 2312 2322 O
of 112 114 2323 2325 O
DNA 115 118 2326 2329 B-treatment
hypomethylator 119 133 2330 2344 I-treatment
treatment 134 143 2345 2354 I-treatment
during 144 150 2355 2361 O
the 151 154 2362 2365 O
past 155 159 2366 2370 B-upper_bound
2 160 161 2371 2372 I-upper_bound
years 162 167 2373 2378 I-upper_bound
, 167 168 2378 2379 O
OR 169 171 2380 2382 O
failure 172 179 2383 2390 O
to 180 182 2391 2393 O
achieve 183 190 2394 2401 O
complete 191 199 2402 2410 O
or 200 202 2411 2413 O
partial 203 210 2414 2421 O
response 211 219 2422 2430 O
or 220 222 2431 2433 O
hematological 223 236 2434 2447 O
improvement 237 248 2448 2459 O
( 249 250 2460 2461 O
see 250 253 2461 2464 O
section 254 261 2465 2472 O
12.4 262 266 2473 2477 O
) 266 267 2477 2478 O
after 268 273 2479 2484 O
at 274 276 2485 2487 O
least 277 282 2488 2493 O
six 283 286 2494 2497 O
cycles 287 293 2498 2504 O
of 294 296 2505 2507 O
azacytidine 297 308 2508 2519 B-treatment
or 309 311 2520 2522 O
four 312 316 2523 2527 O
cycles 317 323 2528 2534 O
of 324 326 2535 2537 O
decitabine 327 337 2538 2548 B-treatment
administered 338 350 2549 2561 O
during 351 357 2562 2568 O
the 358 361 2569 2572 O
past 362 366 2573 2577 O
2 367 368 2578 2579 O
years 369 374 2580 2585 O
, 374 375 2585 2586 O
OR 376 378 2587 2589 O
intolerance 379 390 2590 2601 O
to 391 393 2602 2604 O
azacytidine 394 405 2605 2616 O
or 406 408 2617 2619 O
decitabine 409 419 2620 2630 O
. 419 420 2630 2631 O
MDS 421 424 2632 2635 O
patients 425 433 2636 2644 O
with 434 438 2645 2649 O
isolated 439 447 2650 2658 O
5q- 448 451 2659 2662 O
abnormalities 452 465 2663 2676 O
that 466 470 2677 2681 O
meet 471 475 2682 2686 O
these 476 481 2687 2692 O
criteria 482 490 2693 2701 O
after 491 496 2702 2707 O
lenalidomide 497 509 2708 2720 B-treatment
therapy 510 517 2721 2728 I-treatment
and 518 521 2729 2732 O
DNA 522 525 2733 2736 B-treatment
hypomethylator 526 540 2737 2751 I-treatment
therapy 541 548 2752 2759 I-treatment
are 549 552 2760 2763 O
also 553 557 2764 2768 O
eligible 558 566 2769 2777 O

Patients 0 8 2778 2786 O
with 9 13 2787 2791 O
known 14 19 2792 2797 O
CNS 20 23 2798 2801 B-cancer
involvement 24 35 2802 2813 I-cancer
with 36 40 2814 2818 I-cancer
AML 41 44 2819 2822 I-cancer
are 45 48 2823 2826 O
eligible 49 57 2827 2835 O
provided 58 66 2836 2844 O
that 67 71 2845 2849 O
they 72 76 2850 2854 O
have 77 81 2855 2859 O
been 82 86 2860 2864 O
treated 87 94 2865 2872 O
and 95 98 2873 2876 O
CSF 99 102 2877 2880 O
is 103 105 2881 2883 O
clear 106 111 2884 2889 O
for 112 115 2890 2893 O
at 116 118 2894 2896 O
least 119 124 2897 2902 O
2 125 126 2903 2904 B-lower_bound
weeks 127 132 2905 2910 I-lower_bound
prior 133 138 2911 2916 I-lower_bound
to 139 141 2917 2919 O
enrollment 142 152 2920 2930 O
into 153 157 2931 2935 O
the 158 161 2936 2939 O
study 162 167 2940 2945 O

Pregnant 0 8 2946 2954 B-pregnancy

Received 0 8 2955 2963 O
any 9 12 2964 2967 O
investigational 13 28 2968 2983 B-treatment
drugs 29 34 2984 2989 I-treatment
within 35 41 2990 2996 O
the 42 45 2997 3000 O
14 46 48 3001 3003 B-upper_bound
days 49 53 3004 3008 I-upper_bound
prior 54 59 3009 3014 I-upper_bound
to 60 62 3015 3017 O
the 63 66 3018 3021 O
first 67 72 3022 3027 O
dose 73 77 3028 3032 O
of 78 80 3033 3035 O
fludarabine 81 92 3036 3047 B-treatment

Refractory 0 10 3048 3058 O
AML 11 14 3059 3062 B-cancer
without 15 22 3063 3070 O
CR 23 25 3071 3073 O
after 26 31 3074 3079 O
induction 32 41 3080 3089 B-treatment
therapy 42 49 3090 3097 I-treatment
( 50 51 3098 3099 O
primary 51 58 3099 3106 O
induction 59 68 3107 3116 O
failure 69 76 3117 3124 O
) 76 77 3124 3125 O
or 78 80 3126 3128 O
relapsed 81 89 3129 3137 O
AML 90 93 3138 3141 O
after 94 99 3142 3147 O
obtaining 100 109 3148 3157 O
a 110 111 3158 3159 O
CR 112 114 3160 3162 O

Refractory 0 10 3163 3173 O
AML 11 14 3174 3177 B-cancer
without 15 22 3178 3185 O
complete 23 31 3186 3194 O
remission 32 41 3195 3204 O
( 42 43 3205 3206 O
CR 43 45 3206 3208 O
) 45 46 3208 3209 O
after 47 52 3210 3215 O
induction 53 62 3216 3225 B-treatment
therapy 63 70 3226 3233 I-treatment
( 71 72 3234 3235 O
primary 72 79 3235 3242 O
induction 80 89 3243 3252 O
failure 90 97 3253 3260 O
) 97 98 3260 3261 O
or 99 101 3262 3264 O
relapsed 102 110 3265 3273 O
AML 111 114 3274 3277 O
after 115 120 3278 3283 O
obtaining 121 130 3284 3293 O
a 131 132 3294 3295 O
CR 133 135 3296 3298 O

Relapsed 0 8 3299 3307 O
after 9 14 3308 3313 O
allogeneic 15 25 3314 3324 B-treatment
transplantation 26 41 3325 3340 I-treatment

Uncontrolled 0 12 3341 3353 O
angina 13 19 3354 3360 B-chronic_disease
, 19 20 3360 3361 O
severe 21 27 3362 3368 O
uncontrolled 28 40 3369 3381 O
ventricular 41 52 3382 3393 B-chronic_disease
arrhythmias 53 64 3394 3405 I-chronic_disease
, 64 65 3405 3406 O
or 66 68 3407 3409 O
EKG 69 72 3410 3413 O
suggestive 73 83 3414 3424 O
of 84 86 3425 3427 O
acute 87 92 3428 3433 O
ischemia 93 101 3434 3442 B-chronic_disease
or 102 104 3443 3445 O
active 105 111 3446 3452 O
conduction 112 122 3453 3463 B-chronic_disease
system 123 129 3464 3470 I-chronic_disease
abnormalities 130 143 3471 3484 I-chronic_disease

Uncontrolled 0 12 3485 3497 O
bacterial 13 22 3498 3507 B-chronic_disease
or 23 25 3508 3510 O
viral 26 31 3511 3516 B-chronic_disease
infections 32 42 3517 3527 I-chronic_disease
, 42 43 3527 3528 O
or 44 46 3529 3531 O
known 47 52 3532 3537 O
HIV 53 56 3538 3541 B-chronic_disease
, 56 57 3541 3542 O
Hepatitis 58 67 3543 3552 B-chronic_disease
B 68 69 3553 3554 I-chronic_disease
or 70 72 3555 3557 I-chronic_disease
C 73 74 3558 3559 I-chronic_disease
infection 75 84 3560 3569 I-chronic_disease

Women 0 5 3570 3575 B-gender
of 6 8 3576 3578 O
childbearing 9 21 3579 3591 O
potential 22 31 3592 3601 O
must 32 36 3602 3606 O
have 37 41 3607 3611 O
a 42 43 3612 3613 O
negative 44 52 3614 3622 O
pregnancy 53 62 3623 3632 B-pregnancy
test 63 67 3633 3637 O
within 68 74 3638 3644 O
28 75 77 3645 3647 B-upper_bound
days 78 82 3648 3652 I-upper_bound
prior 83 88 3653 3658 I-upper_bound
to 89 91 3659 3661 O
study 92 97 3662 3667 O
registration 98 110 3668 3680 O

cytoreductive 0 13 3681 3694 B-treatment
therapies 14 23 3695 3704 I-treatment
including 24 33 3705 3714 O
leukapheresis 34 47 3715 3728 B-treatment
or 48 50 3729 3731 O
hydroxyurea 51 62 3732 3743 B-treatment

